BAKER BROS. ADVISORS LP Q1 2022 Filing
Filed May 16, 2022
Portfolio Value
$17.4T
Holdings
118
Report Date
Q1 2022
Filing Type
13F-HR
All Holdings (118 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | BNRBurning Rock Biotech Limited | 209,131 | $1.9B | 0.01% | |
| 102 | SNDXSyndax Pharmaceuticals, Inc. | 110,729 | $1.9B | 0.01% | |
| 103 | AKROAkero Therapeutics, Inc. | 118,378 | $1.7B | 0.01% | |
| 104 | CABACabaletta Bio, Inc. | 662,063 | $1.3B | 0.01% | |
| 105 | —NexImmune, Inc. | 294,117 | $1.2B | 0.01% | |
| 106 | —Epizyme, Inc. | 1,000,000 | $1.1B | 0.01% | |
| 107 | TARAProtara Therapeutics, Inc. | 199,671 | $1.0B | 0.01% | |
| 108 | —Genetron Holdings Limited | 455,306 | $997.0M | 0.01% | |
| 109 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $979.0M | 0.01% | |
| 110 | —Vincerx Pharma, Inc. | 241,379 | $966.0M | 0.01% | |
| 111 | SERASera Prognostics, Inc. | 201,562 | $764.0M | 0.00% | |
| 112 | OYSTOyster Point Pharma, Inc. | 61,424 | $715.0M | 0.00% | |
| 113 | FHTXFoghorn Therapeutics Inc. | 45,027 | $686.0M | 0.00% | |
| 114 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $538.0M | 0.00% | |
| 115 | INZYInozyme Pharma, Inc. | 106,999 | $438.0M | 0.00% | |
| 116 | PASGPassage Bio, Inc. | 117,161 | $363.0M | 0.00% | |
| 117 | —LogicBio Therapeutics, Inc. | 451,478 | $307.0M | 0.00% | |
| 118 | SRZNWSurrozen, Inc. | 833,333 | $208.0M | 0.00% |
PreviousPage 2 of 2